{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T19:13:30Z","timestamp":1784142810512,"version":"3.55.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,25]],"date-time":"2017-08-25T00:00:00Z","timestamp":1503619200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jdcjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.jdiacomp.2017.08.005","type":"journal-article","created":{"date-parts":[[2017,8,12]],"date-time":"2017-08-12T15:15:13Z","timestamp":1502550913000},"page":"1719-1727","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":87,"title":["A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data"],"prefix":"10.1016","volume":"31","author":[{"given":"Evgenia","family":"Gourgari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin E.","family":"Wilhelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Hassanzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanita R.","family":"Aroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Shoulson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2017.08.005_bb0005","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa1610187","article-title":"Incidence trends of type 1 and type 2 diabetes among youths, 2002\u20132012","volume":"376","author":"Mayer-Davis","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2017.08.005_bb0010","author":"American Diabetes A"},{"key":"10.1016\/j.jdiacomp.2017.08.005_bb0015","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.2337\/dc13-0356","article-title":"Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE)","volume":"36","author":"Nathan","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2017.08.005_bb0020","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.2337\/dc15-2399","article-title":"Complications trial\/epidemiology of diabetes I, complications study research G. Mortality in type 1 diabetes in the DCCT\/EDIC versus the general population","volume":"39","author":"Diabetes C","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2017.08.005_bb0025","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1056\/NEJMoa1310799","article-title":"Changes in diabetes-related complications in the United States, 1990\u20142010","volume":"370","author":"Gregg","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2017.08.005_bb0030","doi-asserted-by":"crossref","first-page":"971","DOI":"10.2337\/dc15-0078","article-title":"Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D exchange clinic registry","volume":"38","author":"Miller","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2017.08.005_bb0035","series-title":"Guidance for Industry: Diabetes Mellitus \u2014 Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes","author":"FDA","year":"2008"},{"key":"10.1016\/j.jdiacomp.2017.08.005_bb0040","author":"FDA"},{"key":"10.1016\/j.jdiacomp.2017.08.005_bb0045","author":"WebMD"},{"key":"10.1016\/j.jdiacomp.2017.08.005_bb0050","author":"CenterWatch"},{"key":"10.1016\/j.jdiacomp.2017.08.005_bb0055","author":"Medscape"},{"key":"10.1016\/j.jdiacomp.2017.08.005_bb0060","author":"FDA"},{"key":"10.1016\/j.jdiacomp.2017.08.005_bb0065","author":"FDA"},{"key":"10.1016\/j.jdiacomp.2017.08.005_bb0070","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1001\/jama.2015.16174","article-title":"Effect of metformin added to insulin on glycemic control among overweight\/obese adolescents with type 1 diabetes: a randomized clinical trial","volume":"314","author":"Libman","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jdiacomp.2017.08.005_bb0075","doi-asserted-by":"crossref","first-page":"S177","DOI":"10.2337\/dc11-s215","article-title":"Treatment of type 2 diabetes in youth","volume":"34","author":"Flint","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2017.08.005_bb0080","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jpeds.2015.11.015","article-title":"Treatment options for type 2 diabetes in youth remain limited","volume":"170","author":"Meehan","year":"2016","journal-title":"J Pediatr"},{"key":"10.1016\/j.jdiacomp.2017.08.005_bb0085","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2337\/dc15-1649","article-title":"Expanding treatment options for youth with type 2 diabetes: current problems and proposed solutions: a white paper from the NICHD Diabetes Working Group","volume":"39","author":"Tamborlane","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2017.08.005_bb0090","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.2337\/dc09-0773","article-title":"Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes","volume":"32","author":"Rother","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2017.08.005_bb0095","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S2213-8587(16)00039-5","article-title":"Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus","volume":"4","author":"Frandsen","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jdiacomp.2017.08.005_bb0100","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.2337\/dc15-1037","article-title":"Twelve-week treatment with Liraglutide as add-on to insulin in normal-weight patients with poorly controlled type 1 diabetes: a randomized, placebo-controlled, double-blind parallel study","volume":"38","author":"Frandsen","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2017.08.005_bb0105","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.2337\/dc15-1730","article-title":"Efficacy and safety of Canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes","volume":"38","author":"Henry","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2017.08.005_bb0110","doi-asserted-by":"crossref","first-page":"746","DOI":"10.2337\/diacare.29.03.06.dc05-2181","article-title":"The effect of rosiglitazone on overweight subjects with type 1 diabetes","volume":"29","author":"Orchard","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2017.08.005_bb0115","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","article-title":"Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"38","author":"Inzucchi","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2017.08.005_bb0120","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2017.08.005_bb0125","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12933-016-0456-8","article-title":"Current perspectives on cardiovascular outcome trials in diabetes","volume":"15","author":"Schnell","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2017.08.005_bb0130","doi-asserted-by":"crossref","first-page":"840","DOI":"10.5114\/aoms.2015.53304","article-title":"Sulfonylureas and their use in clinical practice","volume":"11","author":"Sola","year":"2015","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.jdiacomp.2017.08.005_bb0135","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/jama.1975.03250080015008","article-title":"Settling the UGDP controversy?","volume":"232","author":"Bradley","year":"1975","journal-title":"JAMA"},{"key":"10.1016\/j.jdiacomp.2017.08.005_bb0140","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/S0140-6736(14)62225-X","article-title":"Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial","volume":"385","author":"Zannad","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2017.08.005_bb0145","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of Sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2017.08.005_bb0150","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/jamacardio.2016.0184","article-title":"The safety of dipeptidyl peptidase 4 inhibitors and the risk for heart failure","volume":"1","author":"Scirica","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jdiacomp.2017.08.005_bb0155","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2017.08.005_bb0160","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2017.08.005_bb0165","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-Year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2017.08.005_bb0170","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2017.08.005_bb0175","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2017.08.005_bb0180","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872717302003?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872717302003?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T04:04:28Z","timestamp":1659326668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872717302003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S1056872717302003"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2017.08.005","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2017.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors.","name":"copyright","label":"Copyright"}]}}